[Successful treatment with reduced-intensity stem cell transplantation for primary myelofibrosis].
A 60-year-old man was found to have anemia and leukocytosis from a health examination, and diagnosed with primary myelofibrosis (PMF). He was treated with low-dose melphalan but required frequent transfusions of red blood cells, and his splenomegaly enlarged. He received reduced-intensity stem cell transplantation (RIST)from an HLA-identical unrelated donor. The recovery of hematopoiesis was delayed due to the small number of transplanted cells (0.4 x 10(8)/kg). Splenomegaly and myelofibrosis gradually improved, and transfusion was not necessary 6 months later. He died of pneumonia about 1 year after transplantation. However, this case suggests that RIST is an effective treatment for PMF with giant splenomegaly.
Dept. of Hematology, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine.
Satomi
S
Ito
Maki
M
Hagihara
Kenji
K
Motohashi
Atsuo
A
Maruta
Yoshiaki
Y
Ishigatsubo
Seiji
S
Gomi
Heiwa
H
Kanamori
D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D033581:Stem Cell Transplantation; D014057:Tomography, X-Ray Computed
D019653:Myeloablative Agonists; D008558:Melphalan